Skip to content

Developing Online Interventions to Reduce Stigma-Related Stress, Sexual Health, and HIV Risk Among Young Chinese MSM

Developing Efficient Intervention Technologies to Reduce Stigma-Related Stress, Mental Health Problems, and HIV Risk Among Young Chinese MSM

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04718194
Enrollment
120
Registered
2021-01-22
Start date
2021-04-19
Completion date
2022-11-30
Last updated
2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Risk, LGBTQ, Sexual Behavior

Brief summary

This study is a 2-arm RCT that will assess the efficacy of a culturally adapted, 10-session SGM-affirmative, internet-based cognitive behavioral therapy (iCBT) among young men who have sex with men (YMSM) in Hunan province China. The affirmative treatment called ESTEEM is based on a minority stress-focused, CBT framework. In collaboration with colleagues at Central South University (CSU), the investigators will assess whether a culturally adapted version of iCBT ESTEEM demonstrates significant reductions in HIV risk behavior and mental health symptoms (e.g., depression, anxiety) compared to self-monitoring of stress and mood.

Detailed description

The primary objective is to evaluate the preliminary efficacy of a Chinese-adapted version of iCBT ESTEEM on YMSM's sexual health and HIV risk behavior. The secondary objectives of this study are to determine whether iCBT ESTEEM impacts HIV/sexually transmitted infections (STI) results and symptoms of depression and anxiety, as well as whether baseline minority stress exposure moderates treatment efficacy, such that participants with the most minority stress exposure benefit more from iCBT ESTEEM than those in the self-monitoring of stress and mood condition. The proposed prospective study will follow a 2-arm RCT design where 120 Chinese YMSM participants will be randomly assigned to one of two conditions: 1. ESTEEM iCBT: This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks. Modules contain weekly psychoeducational text and vignettes about minority stress and mental health; brief videos illustrating the CBT skills; and homework exercises that therapists review and provide feedback on. Homework exercises include weekly tracking of stress and mood, practicing new skills (e.g., mindfulness, cognitive restructuring), and exercises related to considering the origins of stress and negative emotions that participants may be experiencing. Therapists provide feedback after each homework assignment, including reviewing each participant's treatment goals as part of the first session's homework. Therapists who support this condition will be instructed to incorporate SGM-specific content and feedback into homework reviews. In the US, modules were adapted directly from the in-person materials (e.g., therapist manual, participant handouts) used in our previously successful trials of this treatment. The treatment has also been recently culturally adapted for in-person treatment among Chinese YMSM and found to be acceptable and feasible. 2. Self-monitoring control: In this control condition, participants will be asked to indicate their past 7-day mood, stress experiences, and mental and behavioral health on an online survey. This type of self-monitoring has been shown to yield improvement in behavioral health outcomes. Self-reporting SGM stress experiences has also been shown to produce reductions in depression symptoms over time. Participants will record these experiences once per week for 10 weeks. Before the full trial is launched, the investigators will ensure comprehension of the ESTEEM iCBT online module material with 10 separate YMSM, as well as gather their feedback on the usability of the iCBT online platform.

Interventions

BEHAVIORALESTEEM iCBT

The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.

Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Central South University
CollaboratorOTHER
Fogarty International Center of the National Institute of Health
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
16 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* 16-30 years old * Live in Hunan province China * Current gender identity as male * Report past 12-month sex with men * Be confirmed HIV-negative upon at-home testing * Report past 3-month condomless/PrEP-less anal sex * Past-week symptoms of depression or anxiety using the Brief Symptom Inventory-4 cutoff of 2.5 on either the depression subscale, anxiety subscale, or both * No past 3-month mental health services of more than 2 visits per month * Weekly access to internet on a laptop, desktop, or tablet device * Ability to read, write, and speak in Mandarin * Provision of informed consent

Exclusion criteria

* Current active suicidality or homicidality (defined as active intent or concrete plan, as opposed to passive ideation) * Evidence of active and untreated mania or psychosis that could interfere with the participant's ability to volitionally consent to research or interfere with their ability to safely and reliably complete research

Design outcomes

Primary

MeasureTime frameDescription
Change in Number of Past 90-Day Condomless Anal Sex ActsBaseline, 4 months, 8 monthsThe Timeline Follow-Back (TLFB) assesses retrospective estimates of HIV-related sexual behavior in the past 30 days. The TLFB was originally developed in interview format, but has been adapted as online self-report questionnaire. Participants report on daily partner type (e.g. main, casual), type of sexual behavior (e.g. insertive anal sex, receptive anal sex, oral sex), and condom use. The TLFB has good test-retest reliability, convergent validity, and agreement with collateral reports for HIV-related sexual behavior. Administration time ranges from 10-30 minutes. For this primary outcome measure, condomless anal sex (CAS) with main or casual partners will be determined. The primary comparison will be change in the number of CAS acts from baseline to 8 months post-baseline.

Secondary

MeasureTime frameDescription
Change in Acceptance ConcernsBaseline, 4 months, 8 monthsAcceptance concerns of sexual minority identity will be assessed using the Acceptance Concerns subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total scores ranging from 1 to 6. Higher scores indicate higher acceptance concerns.
Change in Safer SexBaseline, 4 months, 8 monthsThe Safer Sex Questionnaire is a psychometrically validated measure and consists of 13-items based on a 5-point Likert scale assessing one's confidence in avoiding having anal sex without a condom in various contexts. Scores are summed for a total score, ranging from 13 to 65, with higher scores are indicative of greater safer sex self-efficacy.
Change in HIV Test ResultsBaseline, 4 months, 8 monthsParticipants will be provided with self-administered rapid HIV testing kits at baseline and 8-months post-baseline to assess for incidence of HIV.
Change in Syphilis Test ResultsBaseline, 4 months, 8 monthsParticipants will be provided with self-administered rapid syphilis testing kits at baseline and 8-months post-baseline to assess for incidence of syphilis.
Change in Number of Past 90-Day Condomless Anal Sex Acts With Casual PartnersBaseline, 4 months, 8 monthsThe Timeline Follow-Back (TLFB) assesses retrospective estimates of HIV-related sexual behavior in the past 30 days. The TLFB was originally developed in interview format, but has been adapted as online self-report questionnaire. Participants report on daily partner type (e.g. main, casual), type of sexual behavior (e.g. insertive anal sex, receptive anal sex, oral sex), and condom use. The TLFB has good test-retest reliability, convergent validity, and agreement with collateral reports for HIV-related sexual behavior. Administration time ranges from 10-30 minutes. For this secondary outcome measure, condomless anal sex (CAS) with casual partners only will be determined.
Change in DepressionBaseline, 4 months, 8 monthsDepression will be measured using the Patient Health Questionnaire-9 (PHQ-9). A sum score of 9 items indicates depression severity, with higher scores indicating higher severity and a scores ranging from 0-27. A 10th item indicates functional impairment. A cutoff score of 7 or more indicates high likelihood of a depressive episode.
Change in AnxietyBaseline, 4 months, 8 monthsAnxiety will be measured using the Generalized Anxiety Disorder-7 scale (GAD-7). A sum score of 7 items indicates anxiety severity, with higher scores indicating higher severity and scores ranging from 0 to 21. An 8th item indicates functional impairment. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate, and severe anxiety, respectively.
Change in Disordered Alcohol UseBaseline, 4 months, 8 monthsDisordered alcohol use will be assessed using the Alcohol Use Disorders Identification (AUDIT) instrument. The AUDIT consists of 10 items. Items 1 to 9 are scored 0, 1, 2, 3, or 4, and item 10 is scored 0, 2, or 4. Higher scores indicate greater alcohol use, with scores ranging from 0 to 40. Total scores of 8 or more are recommended as indicators of hazardous and harmful alcohol use, as well as possible alcohol dependence.
Change in Disordered Drug UseBaseline, 4 months, 8 monthsDisordered drug use other than alcohol will be assessed using the Drug Use Disorders Identification (DUDIT) instrument. The DUDIT consists of 11 items. Items 1 to 9 are scored 0, 1, 2, 3, or 4, and items 10 and 11 are scored 0, 2, or 4. Higher scores indicate greater drug use, with scores ranging from 0 to 44. A score of 25 points or more is recommended as an indicator of drug dependence.
Change in Suicidal IdeationBaseline, 4 months, 8 monthsSuicidal ideation will be measured using the Suicidal Ideation Attributes Scale (SIDAS). Total SIDAS scores are calculated as the sum of the five items, with controllability (item 2) reverse scored (10=0, 9=1, …, 0=10). Higher scores indicate greater suicidality, with total scores ranging from 0 to 50.
Change in Concealment MotivationBaseline, 4 months, 8 monthsMotivation to conceal sexual minority identity will be assessed using the Concealment Motivation subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total score, ranging from 1 to 6. Higher scores indicate higher concealment motivation.
Change in Internalized HomonegativityBaseline, 4 months, 8 monthsInternalized homonegativity will be assessed using the Internalized Homophobia subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total scores, ranging from 1 to 6. Higher scores indicate higher internalized homonegativity.
Change in Emotion DysregulationBaseline, 4 months, 8 monthsEmotion dysregulation will be assessed using the 18-item Difficulties in Emotion Regulation Scale-Short Form (DERS-SF). Items are rated on a 5-point scale from 1-5; items 1, 4, and 6 are reverse coded. Items are summed for a total score, ranging from 18 to 90, where higher scores indicate higher emotion dysregulation.
Change in Perceived Social SupportBaseline, 4 months, 8 monthsPerceived social support will be measured using the 12-item Multidimensional Scale of Perceived Social Support (MPSS). Items are rated on a 7-point scale from 1-7 and averaged for a total score, ranging from 1 to 7, with higher scores indicating higher perceived social support.
Change in RuminationBaseline, 4 months, 8 monthsRumination will be measured using the 5-item Brooding Subscale of the Ruminative Responses Scale (RRS). Items are rated on a 4-point scale from 1-4 and summed for a total scores, ranging from 5 to 20, with higher scores indicating higher rumination.
Change in HIV/STI TestingBaseline, 4 months, 8 monthsThe Past 4-month HIV/STI Testing Questionnaire consists of 7 multiple choice questions previously developed by the study PI for another study asking participants about their HIV/STI testing history. The questionnaire consists of questions, such as, Have you provided a urine sample as part of any STI test in the last 4 months with response options of yes, no, or I don't remember. Scores were coded with yes being 1 and no being 0, and and a total score was assessed as the average of all scores. Thus, total scores ranged from 0 to 1, with higher scores indicating greater HIV/STI testing in the past 4 months.
Change in Condom UseBaseline, 4 months, 8 monthsThe Decisional Balance for Condom Use Scale is an 18-item psychometrically validated scale measuring one's motivation to increase condom use (e.g., I would feel bad if my friends found out I had sex without a condom), with response options ranging between 1 = not at all to 5 = extremely. Scores are summed for a total scores, ranging from 18 to 90, with lower scores are indicative of greater likelihood to use a condom.

Other

MeasureTime frameDescription
Change in Self-EsteemBaseline, 4 months, 8 monthsAs an exploratory outcome, self-esteem will be measured using the 10-item Rosenberg Self-Esteem Scale. Items are rated on a 4 point scale from 0-3; items 4, 6, 9, 10, and 11 are reverse scored. Items are summed for a total score ranging from 0 to 30, where a higher score indicates greater self-esteem.
Change in Anxiety SeverityBaseline, 4 months, 8 monthsAs an exploratory outcome, anxiety severity will be measured by the Overall Anxiety Severity & Impairment Scale (OASIS). This 5 item measure uses a 0-4 rating scale and sums across the items for a total score ranging from 0 to 20. Higher scores indicate greater severity of anxiety.
Change in Depression SeverityBaseline, 4 months, 8 monthsAs an exploratory outcome, depression severity will be measured using the Overall Depression Severity & Impairment Scale (ODSIS). This 5 item measure uses a 0-4 rating scale and sums across the items for a total score ranging from 0 to 20. Higher scores indicate greater severity of depression.

Countries

China

Participant flow

Recruitment details

Participants were recruited via online and paper advertisements on social networking platforms and in the lobbies of LGBTQ+ friendly organizations. 425 prospective participants completed the initial online screener.

Pre-assignment details

All 120 participants who completed consent and were enrolled logged into the iCBT platform, completed the baseline survey, and were randomized.

Participants by arm

ArmCount
ESTEEM iCBT
ESTEEM iCBT: The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
60
Self-monitoring
Self-monitoring control: Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
60
Total120

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up30
Overall StudyWithdrawal by Subject30

Baseline characteristics

CharacteristicSelf-monitoringTotalESTEEM iCBT
Age, Continuous22.72 years
STANDARD_DEVIATION 3.09
23.22 years
STANDARD_DEVIATION 3.26
23.73 years
STANDARD_DEVIATION 3.36
Education Degree
College/four-year university
47 Participants91 Participants44 Participants
Education Degree
Graduate school or above
6 Participants13 Participants7 Participants
Education Degree
High school/vocational school
6 Participants15 Participants9 Participants
Education Degree
Junior high school or less
1 Participants1 Participants0 Participants
Employment Status
Full-time job
29 Participants55 Participants26 Participants
Employment Status
Part-time job
4 Participants9 Participants5 Participants
Employment Status
Student
24 Participants50 Participants26 Participants
Employment Status
Unemployed
3 Participants6 Participants3 Participants
Estimated Income Per Month
3000-5000
17 Participants31 Participants14 Participants
Estimated Income Per Month
<3000RMB
29 Participants59 Participants30 Participants
Estimated Income Per Month
5000-800
8 Participants17 Participants9 Participants
Estimated Income Per Month
>8000RMB
6 Participants13 Participants7 Participants
Marital/Relationship Status
Divorced
0 Participants2 Participants2 Participants
Marital/Relationship Status
Married
3 Participants5 Participants2 Participants
Marital/Relationship Status
Single, but having regular partner
33 Participants67 Participants34 Participants
Marital/Relationship Status
Single, without a regular partner
24 Participants46 Participants22 Participants
Race/Ethnicity, Customized
Ethnicity
Han nationality
55 Participants113 Participants58 Participants
Race/Ethnicity, Customized
Ethnicity
Hmong/Miao minority
1 Participants3 Participants2 Participants
Race/Ethnicity, Customized
Ethnicity
Hui minority
1 Participants1 Participants0 Participants
Race/Ethnicity, Customized
Ethnicity
Tujia minority
3 Participants3 Participants0 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
60 Participants120 Participants60 Participants
Sexual Orientation
Bisexual
7 Participants10 Participants3 Participants
Sexual Orientation
Gay/homosexual
53 Participants110 Participants57 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 600 / 60
other
Total, other adverse events
0 / 600 / 60
serious
Total, serious adverse events
0 / 600 / 60

Outcome results

Primary

Change in Number of Past 90-Day Condomless Anal Sex Acts

The Timeline Follow-Back (TLFB) assesses retrospective estimates of HIV-related sexual behavior in the past 30 days. The TLFB was originally developed in interview format, but has been adapted as online self-report questionnaire. Participants report on daily partner type (e.g. main, casual), type of sexual behavior (e.g. insertive anal sex, receptive anal sex, oral sex), and condom use. The TLFB has good test-retest reliability, convergent validity, and agreement with collateral reports for HIV-related sexual behavior. Administration time ranges from 10-30 minutes. For this primary outcome measure, condomless anal sex (CAS) with main or casual partners will be determined. The primary comparison will be change in the number of CAS acts from baseline to 8 months post-baseline.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex ActsBaseline1.98 condomless anal sex actsStandard Deviation 3.78
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex Acts4-Month Post-Baseline0.58 condomless anal sex actsStandard Deviation 1.06
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex Acts8-Month Post-Baseline0.50 condomless anal sex actsStandard Deviation 1.22
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex ActsBaseline1.80 condomless anal sex actsStandard Deviation 2.34
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex Acts4-Month Post-Baseline0.80 condomless anal sex actsStandard Deviation 2.04
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex Acts8-Month Post-Baseline0.65 condomless anal sex actsStandard Deviation 1.36
Secondary

Change in Acceptance Concerns

Acceptance concerns of sexual minority identity will be assessed using the Acceptance Concerns subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total scores ranging from 1 to 6. Higher scores indicate higher acceptance concerns.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Acceptance ConcernsBaseline4.73 score on a scaleStandard Deviation 1.23
ESTEEM iCBTChange in Acceptance Concerns4-Month Post-Baseline4.38 score on a scaleStandard Deviation 1.18
ESTEEM iCBTChange in Acceptance Concerns8-Month Post-Baseline4.36 score on a scaleStandard Deviation 1.4
Self-monitoringChange in Acceptance ConcernsBaseline4.63 score on a scaleStandard Deviation 1.05
Self-monitoringChange in Acceptance Concerns4-Month Post-Baseline4.75 score on a scaleStandard Deviation 1.05
Self-monitoringChange in Acceptance Concerns8-Month Post-Baseline4.53 score on a scaleStandard Deviation 1.11
Secondary

Change in Anxiety

Anxiety will be measured using the Generalized Anxiety Disorder-7 scale (GAD-7). A sum score of 7 items indicates anxiety severity, with higher scores indicating higher severity and scores ranging from 0 to 21. An 8th item indicates functional impairment. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate, and severe anxiety, respectively.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in AnxietyBaseline9.55 units on a scaleStandard Deviation 5.05
ESTEEM iCBTChange in Anxiety4-Month Post Baseline5.72 units on a scaleStandard Deviation 3.77
ESTEEM iCBTChange in Anxiety8-Month Post Baseline5.54 units on a scaleStandard Deviation 3.34
Self-monitoringChange in AnxietyBaseline9.03 units on a scaleStandard Deviation 5.06
Self-monitoringChange in Anxiety4-Month Post Baseline8.80 units on a scaleStandard Deviation 4.64
Self-monitoringChange in Anxiety8-Month Post Baseline8.47 units on a scaleStandard Deviation 4.22
Secondary

Change in Concealment Motivation

Motivation to conceal sexual minority identity will be assessed using the Concealment Motivation subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total score, ranging from 1 to 6. Higher scores indicate higher concealment motivation.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Concealment MotivationBaseline4.66 score on a scaleStandard Deviation 1.27
ESTEEM iCBTChange in Concealment Motivation4-Month Post-Baseline4.59 score on a scaleStandard Deviation 1.23
ESTEEM iCBTChange in Concealment Motivation8-Month Post-Baseline4.55 score on a scaleStandard Deviation 1.23
Self-monitoringChange in Concealment MotivationBaseline4.36 score on a scaleStandard Deviation 1.25
Self-monitoringChange in Concealment Motivation4-Month Post-Baseline4.40 score on a scaleStandard Deviation 1.25
Self-monitoringChange in Concealment Motivation8-Month Post-Baseline4.44 score on a scaleStandard Deviation 1.22
Secondary

Change in Condom Use

The Decisional Balance for Condom Use Scale is an 18-item psychometrically validated scale measuring one's motivation to increase condom use (e.g., I would feel bad if my friends found out I had sex without a condom), with response options ranging between 1 = not at all to 5 = extremely. Scores are summed for a total scores, ranging from 18 to 90, with lower scores are indicative of greater likelihood to use a condom.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Condom UseBaseline61.2 score on a scaleStandard Deviation 8.29
ESTEEM iCBTChange in Condom Use4-Month Post-Baseline59.1 score on a scaleStandard Deviation 9.65
ESTEEM iCBTChange in Condom Use8-Month Post-Baseline57.4 score on a scaleStandard Deviation 8.04
Self-monitoringChange in Condom UseBaseline61.5 score on a scaleStandard Deviation 10.4
Self-monitoringChange in Condom Use4-Month Post-Baseline60.6 score on a scaleStandard Deviation 9.99
Self-monitoringChange in Condom Use8-Month Post-Baseline59.3 score on a scaleStandard Deviation 10
Secondary

Change in Depression

Depression will be measured using the Patient Health Questionnaire-9 (PHQ-9). A sum score of 9 items indicates depression severity, with higher scores indicating higher severity and a scores ranging from 0-27. A 10th item indicates functional impairment. A cutoff score of 7 or more indicates high likelihood of a depressive episode.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in DepressionBaseline12.40 units on a scaleStandard Deviation 5.7
ESTEEM iCBTChange in Depression4-Month Post-Baseline8.33 units on a scaleStandard Deviation 3.85
ESTEEM iCBTChange in Depression8-Month Post-Baseline7.28 units on a scaleStandard Deviation 4.47
Self-monitoringChange in Depression4-Month Post-Baseline10.00 units on a scaleStandard Deviation 4.74
Self-monitoringChange in Depression8-Month Post-Baseline10.00 units on a scaleStandard Deviation 3.98
Self-monitoringChange in DepressionBaseline10.40 units on a scaleStandard Deviation 5.28
Secondary

Change in Disordered Alcohol Use

Disordered alcohol use will be assessed using the Alcohol Use Disorders Identification (AUDIT) instrument. The AUDIT consists of 10 items. Items 1 to 9 are scored 0, 1, 2, 3, or 4, and item 10 is scored 0, 2, or 4. Higher scores indicate greater alcohol use, with scores ranging from 0 to 40. Total scores of 8 or more are recommended as indicators of hazardous and harmful alcohol use, as well as possible alcohol dependence.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Disordered Alcohol UseBaseline4.32 units on a scaleStandard Deviation 5.47
ESTEEM iCBTChange in Disordered Alcohol Use4-Month Post-Baseline3.44 units on a scaleStandard Deviation 4.57
ESTEEM iCBTChange in Disordered Alcohol Use8-Month Post-Baseline2.43 units on a scaleStandard Deviation 3.52
Self-monitoringChange in Disordered Alcohol UseBaseline4.88 units on a scaleStandard Deviation 5.87
Self-monitoringChange in Disordered Alcohol Use4-Month Post-Baseline4.68 units on a scaleStandard Deviation 5.53
Self-monitoringChange in Disordered Alcohol Use8-Month Post-Baseline5.30 units on a scaleStandard Deviation 5.89
Secondary

Change in Disordered Drug Use

Disordered drug use other than alcohol will be assessed using the Drug Use Disorders Identification (DUDIT) instrument. The DUDIT consists of 11 items. Items 1 to 9 are scored 0, 1, 2, 3, or 4, and items 10 and 11 are scored 0, 2, or 4. Higher scores indicate greater drug use, with scores ranging from 0 to 44. A score of 25 points or more is recommended as an indicator of drug dependence.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Disordered Drug UseBaseline1.38 units on a scaleStandard Deviation 2.99
ESTEEM iCBTChange in Disordered Drug Use4-Month Post-Baseline0.91 units on a scaleStandard Deviation 2.17
ESTEEM iCBTChange in Disordered Drug Use8-Month Post-Baseline0.61 units on a scaleStandard Deviation 1.39
Self-monitoringChange in Disordered Drug UseBaseline1.97 units on a scaleStandard Deviation 3.82
Self-monitoringChange in Disordered Drug Use4-Month Post-Baseline1.40 units on a scaleStandard Deviation 3.03
Self-monitoringChange in Disordered Drug Use8-Month Post-Baseline1.33 units on a scaleStandard Deviation 2.91
Secondary

Change in Emotion Dysregulation

Emotion dysregulation will be assessed using the 18-item Difficulties in Emotion Regulation Scale-Short Form (DERS-SF). Items are rated on a 5-point scale from 1-5; items 1, 4, and 6 are reverse coded. Items are summed for a total score, ranging from 18 to 90, where higher scores indicate higher emotion dysregulation.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Emotion DysregulationBaseline55.9 score on a scaleStandard Deviation 9.64
ESTEEM iCBTChange in Emotion Dysregulation4-Month Post-Baseline50.0 score on a scaleStandard Deviation 11.5
ESTEEM iCBTChange in Emotion Dysregulation8-Month Post-Baseline48.2 score on a scaleStandard Deviation 10.6
Self-monitoringChange in Emotion DysregulationBaseline54.7 score on a scaleStandard Deviation 10.7
Self-monitoringChange in Emotion Dysregulation4-Month Post-Baseline55.2 score on a scaleStandard Deviation 10
Self-monitoringChange in Emotion Dysregulation8-Month Post-Baseline53.0 score on a scaleStandard Deviation 10.2
Secondary

Change in HIV/STI Testing

The Past 4-month HIV/STI Testing Questionnaire consists of 7 multiple choice questions previously developed by the study PI for another study asking participants about their HIV/STI testing history. The questionnaire consists of questions, such as, Have you provided a urine sample as part of any STI test in the last 4 months with response options of yes, no, or I don't remember. Scores were coded with yes being 1 and no being 0, and and a total score was assessed as the average of all scores. Thus, total scores ranged from 0 to 1, with higher scores indicating greater HIV/STI testing in the past 4 months.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in HIV/STI TestingBaseline0.850 score on a scaleStandard Deviation 0.36
ESTEEM iCBTChange in HIV/STI Testing4-Months Post-Baseline0.815 score on a scaleStandard Deviation 0.392
ESTEEM iCBTChange in HIV/STI Testing8-Months Post-Baseline0.870 score on a scaleStandard Deviation 0.339
Self-monitoringChange in HIV/STI TestingBaseline0.867 score on a scaleStandard Deviation 0.343
Self-monitoringChange in HIV/STI Testing4-Months Post-Baseline0.883 score on a scaleStandard Deviation 0.321
Self-monitoringChange in HIV/STI Testing8-Months Post-Baseline0.900 score on a scaleStandard Deviation 0.303
Secondary

Change in HIV Test Results

Participants will be provided with self-administered rapid HIV testing kits at baseline and 8-months post-baseline to assess for incidence of HIV.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
ESTEEM iCBTChange in HIV Test ResultsBaselinePositive0 Participants
ESTEEM iCBTChange in HIV Test ResultsBaselineNegative54 Participants
ESTEEM iCBTChange in HIV Test Results4-Month Post-BaselinePositive0 Participants
ESTEEM iCBTChange in HIV Test Results4-Month Post-BaselineNegative54 Participants
ESTEEM iCBTChange in HIV Test Results8-Month Post-BaselinePositive0 Participants
ESTEEM iCBTChange in HIV Test Results8-Month Post-BaselineNegative54 Participants
Self-monitoringChange in HIV Test Results8-Month Post-BaselinePositive0 Participants
Self-monitoringChange in HIV Test ResultsBaselinePositive0 Participants
Self-monitoringChange in HIV Test Results4-Month Post-BaselineNegative60 Participants
Self-monitoringChange in HIV Test ResultsBaselineNegative60 Participants
Self-monitoringChange in HIV Test Results8-Month Post-BaselineNegative60 Participants
Self-monitoringChange in HIV Test Results4-Month Post-BaselinePositive0 Participants
Secondary

Change in Internalized Homonegativity

Internalized homonegativity will be assessed using the Internalized Homophobia subscale of the Lesbian, Gay, and Bisexual Identity Scale (LGBIS). The three subscale items, rated on a 6-point scale, will be averaged for a total scores, ranging from 1 to 6. Higher scores indicate higher internalized homonegativity.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Internalized HomonegativityBaseline3.68 score on a scaleStandard Deviation 1.6
ESTEEM iCBTChange in Internalized Homonegativity4-Month Post-Baseline3.60 score on a scaleStandard Deviation 1.52
ESTEEM iCBTChange in Internalized Homonegativity8-Month Post-Baseline3.30 score on a scaleStandard Deviation 1.59
Self-monitoringChange in Internalized HomonegativityBaseline3.19 score on a scaleStandard Deviation 1.3
Self-monitoringChange in Internalized Homonegativity4-Month Post-Baseline3.37 score on a scaleStandard Deviation 1.46
Self-monitoringChange in Internalized Homonegativity8-Month Post-Baseline3.22 score on a scaleStandard Deviation 1.37
Secondary

Change in Number of Past 90-Day Condomless Anal Sex Acts With Casual Partners

The Timeline Follow-Back (TLFB) assesses retrospective estimates of HIV-related sexual behavior in the past 30 days. The TLFB was originally developed in interview format, but has been adapted as online self-report questionnaire. Participants report on daily partner type (e.g. main, casual), type of sexual behavior (e.g. insertive anal sex, receptive anal sex, oral sex), and condom use. The TLFB has good test-retest reliability, convergent validity, and agreement with collateral reports for HIV-related sexual behavior. Administration time ranges from 10-30 minutes. For this secondary outcome measure, condomless anal sex (CAS) with casual partners only will be determined.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual PartnersBaseline.58 condomless anal sex actsStandard Deviation 0.98
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual Partners4-Month Post-Baseline.11 condomless anal sex actsStandard Deviation 0.42
ESTEEM iCBTChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual Partners8-Month Post-Baseline0 condomless anal sex actsStandard Deviation 0
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual PartnersBaseline0.50 condomless anal sex actsStandard Deviation 1.4
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual Partners4-Month Post-Baseline0.22 condomless anal sex actsStandard Deviation 0.67
Self-monitoringChange in Number of Past 90-Day Condomless Anal Sex Acts With Casual Partners8-Month Post-Baseline0.08 condomless anal sex actsStandard Deviation 0.46
Secondary

Change in Perceived Social Support

Perceived social support will be measured using the 12-item Multidimensional Scale of Perceived Social Support (MPSS). Items are rated on a 7-point scale from 1-7 and averaged for a total score, ranging from 1 to 7, with higher scores indicating higher perceived social support.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Perceived Social SupportBaseline3.53 score on a scaleStandard Deviation 1.28
ESTEEM iCBTChange in Perceived Social Support4-Month Post-Baseline3.79 score on a scaleStandard Deviation 1.34
ESTEEM iCBTChange in Perceived Social Support8-Month Post-Baseline3.98 score on a scaleStandard Deviation 1.3
Self-monitoringChange in Perceived Social SupportBaseline3.66 score on a scaleStandard Deviation 1.3
Self-monitoringChange in Perceived Social Support4-Month Post-Baseline3.49 score on a scaleStandard Deviation 1.26
Self-monitoringChange in Perceived Social Support8-Month Post-Baseline3.81 score on a scaleStandard Deviation 1.18
Secondary

Change in Rumination

Rumination will be measured using the 5-item Brooding Subscale of the Ruminative Responses Scale (RRS). Items are rated on a 4-point scale from 1-4 and summed for a total scores, ranging from 5 to 20, with higher scores indicating higher rumination.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in RuminationBaseline13.9 score on a scaleStandard Deviation 3.33
ESTEEM iCBTChange in Rumination4-Month Post-Baseline12.6 score on a scaleStandard Deviation 3.12
ESTEEM iCBTChange in Rumination8-Month Post-Baseline12.3 score on a scaleStandard Deviation 2.77
Self-monitoringChange in RuminationBaseline14.2 score on a scaleStandard Deviation 3.13
Self-monitoringChange in Rumination4-Month Post-Baseline13.6 score on a scaleStandard Deviation 3.67
Self-monitoringChange in Rumination8-Month Post-Baseline13.0 score on a scaleStandard Deviation 3.48
Secondary

Change in Safer Sex

The Safer Sex Questionnaire is a psychometrically validated measure and consists of 13-items based on a 5-point Likert scale assessing one's confidence in avoiding having anal sex without a condom in various contexts. Scores are summed for a total score, ranging from 13 to 65, with higher scores are indicative of greater safer sex self-efficacy.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Safer SexBaseline55.5 score on a scaleStandard Deviation 9.46
ESTEEM iCBTChange in Safer Sex4-Months Post-Baseline56.5 score on a scaleStandard Deviation 8.5
ESTEEM iCBTChange in Safer Sex8-Months Post-Baseline58.8 score on a scaleStandard Deviation 7.05
Self-monitoringChange in Safer SexBaseline55.9 score on a scaleStandard Deviation 9.63
Self-monitoringChange in Safer Sex4-Months Post-Baseline57.1 score on a scaleStandard Deviation 9.95
Self-monitoringChange in Safer Sex8-Months Post-Baseline57.9 score on a scaleStandard Deviation 8.53
Secondary

Change in Suicidal Ideation

Suicidal ideation will be measured using the Suicidal Ideation Attributes Scale (SIDAS). Total SIDAS scores are calculated as the sum of the five items, with controllability (item 2) reverse scored (10=0, 9=1, …, 0=10). Higher scores indicate greater suicidality, with total scores ranging from 0 to 50.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Suicidal IdeationBaseline5.07 units on a scaleStandard Deviation 6.7
ESTEEM iCBTChange in Suicidal Ideation4-Month Post-Baseline2.09 units on a scaleStandard Deviation 4.56
ESTEEM iCBTChange in Suicidal Ideation8-Month Post-Baseline1.76 units on a scaleStandard Deviation 3.74
Self-monitoringChange in Suicidal IdeationBaseline5.47 units on a scaleStandard Deviation 7.36
Self-monitoringChange in Suicidal Ideation4-Month Post-Baseline4.17 units on a scaleStandard Deviation 7.3
Self-monitoringChange in Suicidal Ideation8-Month Post-Baseline2.97 units on a scaleStandard Deviation 6.1
Secondary

Change in Syphilis Test Results

Participants will be provided with self-administered rapid syphilis testing kits at baseline and 8-months post-baseline to assess for incidence of syphilis.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
ESTEEM iCBTChange in Syphilis Test ResultsBaselinePositive0 Participants
ESTEEM iCBTChange in Syphilis Test ResultsBaselineNegative54 Participants
ESTEEM iCBTChange in Syphilis Test Results4-Month Post-BaselinePositive0 Participants
ESTEEM iCBTChange in Syphilis Test Results4-Month Post-BaselineNegative54 Participants
ESTEEM iCBTChange in Syphilis Test Results8-Month Post-BaselinePositive0 Participants
ESTEEM iCBTChange in Syphilis Test Results8-Month Post-BaselineNegative54 Participants
Self-monitoringChange in Syphilis Test Results8-Month Post-BaselinePositive1 Participants
Self-monitoringChange in Syphilis Test ResultsBaselinePositive1 Participants
Self-monitoringChange in Syphilis Test Results4-Month Post-BaselineNegative59 Participants
Self-monitoringChange in Syphilis Test ResultsBaselineNegative59 Participants
Self-monitoringChange in Syphilis Test Results8-Month Post-BaselineNegative59 Participants
Self-monitoringChange in Syphilis Test Results4-Month Post-BaselinePositive1 Participants
Other Pre-specified

Change in Anxiety Severity

As an exploratory outcome, anxiety severity will be measured by the Overall Anxiety Severity & Impairment Scale (OASIS). This 5 item measure uses a 0-4 rating scale and sums across the items for a total score ranging from 0 to 20. Higher scores indicate greater severity of anxiety.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Anxiety SeverityBaseline9.10 score on a scaleStandard Deviation 3.23
ESTEEM iCBTChange in Anxiety Severity4-Months Post-Baseline5.78 score on a scaleStandard Deviation 2.66
ESTEEM iCBTChange in Anxiety Severity8-Months Post-Baseline5.19 score on a scaleStandard Deviation 2.39
Self-monitoringChange in Anxiety SeverityBaseline8.80 score on a scaleStandard Deviation 3.06
Self-monitoringChange in Anxiety Severity4-Months Post-Baseline7.57 score on a scaleStandard Deviation 3.59
Self-monitoringChange in Anxiety Severity8-Months Post-Baseline6.82 score on a scaleStandard Deviation 2.63
Other Pre-specified

Change in Depression Severity

As an exploratory outcome, depression severity will be measured using the Overall Depression Severity & Impairment Scale (ODSIS). This 5 item measure uses a 0-4 rating scale and sums across the items for a total score ranging from 0 to 20. Higher scores indicate greater severity of depression.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Depression SeverityBaseline7.80 score on a scaleStandard Deviation 4.15
ESTEEM iCBTChange in Depression Severity4-Months Post-Baseline4.70 score on a scaleStandard Deviation 3.15
ESTEEM iCBTChange in Depression Severity8-Months Post-Baseline3.80 score on a scaleStandard Deviation 2.68
Self-monitoringChange in Depression SeverityBaseline7.03 score on a scaleStandard Deviation 3.45
Self-monitoringChange in Depression Severity4-Months Post-Baseline6.45 score on a scaleStandard Deviation 4.02
Self-monitoringChange in Depression Severity8-Months Post-Baseline5.32 score on a scaleStandard Deviation 3.24
Other Pre-specified

Change in Self-Esteem

As an exploratory outcome, self-esteem will be measured using the 10-item Rosenberg Self-Esteem Scale. Items are rated on a 4 point scale from 0-3; items 4, 6, 9, 10, and 11 are reverse scored. Items are summed for a total score ranging from 0 to 30, where a higher score indicates greater self-esteem.

Time frame: Baseline, 4 months, 8 months

Population: Intent to Treat Population (participants analyzed according to their original treatment assignment regardless of adherence to protocol) for all participants who completed 4/8-month follow-up assessments.

ArmMeasureGroupValue (MEAN)Dispersion
ESTEEM iCBTChange in Self-EsteemBaseline25.3 score on a scaleStandard Deviation 5.46
ESTEEM iCBTChange in Self-Esteem4-Months Post-Baseline27.2 score on a scaleStandard Deviation 4.6
ESTEEM iCBTChange in Self-Esteem8-Months Post-Baseline27.9 score on a scaleStandard Deviation 4.66
Self-monitoringChange in Self-EsteemBaseline25.9 score on a scaleStandard Deviation 4.9
Self-monitoringChange in Self-Esteem4-Months Post-Baseline25.7 score on a scaleStandard Deviation 4.45
Self-monitoringChange in Self-Esteem8-Months Post-Baseline25.4 score on a scaleStandard Deviation 4.48

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026